BR112012033391A2 - kit contraceptivo, método contraceptivo para uma paciente do sexo feminino necessitando do mesmo e composição farmacêutica compreendendo drospirenova. - Google Patents

kit contraceptivo, método contraceptivo para uma paciente do sexo feminino necessitando do mesmo e composição farmacêutica compreendendo drospirenova.

Info

Publication number
BR112012033391A2
BR112012033391A2 BR112012033391A BR112012033391A BR112012033391A2 BR 112012033391 A2 BR112012033391 A2 BR 112012033391A2 BR 112012033391 A BR112012033391 A BR 112012033391A BR 112012033391 A BR112012033391 A BR 112012033391A BR 112012033391 A2 BR112012033391 A2 BR 112012033391A2
Authority
BR
Brazil
Prior art keywords
contraceptive
pharmaceutical composition
need
female patient
drospirenova
Prior art date
Application number
BR112012033391A
Other languages
English (en)
Other versions
BR112012033391A8 (pt
BR112012033391B1 (pt
Inventor
Dominique Drouin
Josê Velada
Philippe Perrin
Original Assignee
Laboratórios León Farma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42671710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012033391(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratórios León Farma S A filed Critical Laboratórios León Farma S A
Priority to BR122019008317-7A priority Critical patent/BR122019008317A2/pt
Publication of BR112012033391A2 publication Critical patent/BR112012033391A2/pt
Publication of BR112012033391A8 publication Critical patent/BR112012033391A8/pt
Publication of BR112012033391B1 publication Critical patent/BR112012033391B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

kit contraceptivo, método contraceptivo para uma paciente do sexo feminino necessitando do mesmo e composição farmacêutica compreendendo drospirenona. a presente invenção refere-se ao campo de composições farmacêuticas e métodos contraceptivos. a presente invenção provê uma composição farmacêutica compreendendo drospirenona caracterizada por uma taxa de dissolução lenta de drospirenona in vitro e um perfil farmacocinético melhorado. o uso da referida composição em métodos contraceptivos e kits também são providos.
BR112012033391-7A 2010-06-29 2011-06-28 Kit contraceptivo, e composição farmacêutica compreendendo drospirenona BR112012033391B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019008317-7A BR122019008317A2 (pt) 2010-06-29 2011-06-28 Kit contraceptivo, método contraceptivo para uma paciente do sexo feminino necessitando do mesmo e composição farmacêutica compreendendo drospirenona

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10305708.9 2010-06-29
EP10305708 2010-06-29
US36839610P 2010-07-28 2010-07-28
US61/368,396 2010-07-28
PCT/EP2011/060795 WO2012000981A1 (en) 2010-06-29 2011-06-28 Pharmaceutical composition comprising drospirenone and contraceptive kit

Publications (3)

Publication Number Publication Date
BR112012033391A2 true BR112012033391A2 (pt) 2016-11-22
BR112012033391A8 BR112012033391A8 (pt) 2018-04-17
BR112012033391B1 BR112012033391B1 (pt) 2020-02-27

Family

ID=42671710

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012033391-7A BR112012033391B1 (pt) 2010-06-29 2011-06-28 Kit contraceptivo, e composição farmacêutica compreendendo drospirenona

Country Status (23)

Country Link
US (6) US11452695B2 (pt)
EP (3) EP3632448B1 (pt)
JP (1) JP5810159B2 (pt)
KR (3) KR20130048227A (pt)
AR (1) AR081670A1 (pt)
BR (1) BR112012033391B1 (pt)
CA (3) CA3061421C (pt)
CY (2) CY1122544T1 (pt)
DK (1) DK3632448T3 (pt)
EA (1) EA028680B1 (pt)
ES (1) ES2908657T3 (pt)
FR (2) FR20C1020I1 (pt)
HR (1) HRP20220332T1 (pt)
HU (3) HUE058176T2 (pt)
LT (2) LT3632448T (pt)
NO (1) NO2020015I1 (pt)
NZ (1) NZ605176A (pt)
PE (2) PE20130780A1 (pt)
PL (2) PL2588114T3 (pt)
PT (1) PT3632448T (pt)
RS (2) RS59826B1 (pt)
SI (2) SI2588114T1 (pt)
WO (1) WO2012000981A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
ES2877186T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
PL3106148T3 (pl) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy
PL3310333T3 (pl) 2015-06-18 2020-07-13 Estetra Sprl Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy
ES2877476T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
EP3108889A1 (en) 2015-06-23 2016-12-28 Philippe Perrin Drospirenone-based contraceptive for a female patient affected with excess weight
HRP20240121T8 (hr) * 2015-06-23 2024-05-10 Laboratorios Leon Farma Sa Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
EP4134082A1 (en) 2021-08-12 2023-02-15 Chemo Research, S.L. Method for treating endometriosis and providing effective contraception
WO2023152658A1 (en) 2022-02-10 2023-08-17 Lupin Limited Slow release drospirenone tablet composition
WO2023165988A1 (en) 2022-03-01 2023-09-07 Chemo Research, S.L. Chewable oral contraceptive

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE69112917T2 (de) 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
GB2256648B (en) 1991-05-29 1995-08-30 Colorcon Ltd Wax polish composition
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
JP4354667B2 (ja) 1999-08-31 2009-10-28 バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ
WO2001052857A1 (en) 2000-01-18 2001-07-26 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
US20040087563A1 (en) 2002-11-05 2004-05-06 Siegfried Mayerhofer Hormone replacement therapy with cardiovascular protection using antialdosteronic progestins
US20050220825A1 (en) 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
EP1980242B1 (en) 2004-03-10 2010-08-11 Bayer Schering Pharma Aktiengesellschaft Liquid compositions as a micro-emulsion pre-concentrate comprising drospirenone moleculary dispersed
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
JP5288796B2 (ja) 2004-07-07 2013-09-11 ワイス・エルエルシー 周期的プロゲスチンレジメン及びキット
EP1625849A1 (en) 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
ITMI20042338A1 (it) 2004-12-06 2005-03-06 Ind Chimica Srl Processo per la preparazione di drospirenone
US20060293295A1 (en) 2005-05-13 2006-12-28 Kai Strothmann Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
US8475838B2 (en) 2005-06-03 2013-07-02 Sandoz Ag Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
TW200727920A (en) 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
ATE403668T1 (de) 2005-07-21 2008-08-15 Bayer Schering Pharma Ag Verfahren zur herstellung von 3-oxo-pregn-4-en-21,17-carbolactonen durch die metallfreie oxidation von 17-(3-hydroxypropyl)-3,17- dihydroxyandrostanen
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
JP2010503632A (ja) * 2006-09-16 2010-02-04 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 経口改良放出製剤
US8741329B2 (en) 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
MX2010008945A (es) 2008-02-13 2010-09-07 Bayer Schering Pharma Ag Sistema de administracion de drogas con efecto estabilizante.
WO2009138224A1 (en) 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same

Also Published As

Publication number Publication date
PE20130780A1 (es) 2013-07-06
WO2012000981A1 (en) 2012-01-05
LT3632448T (lt) 2022-03-25
EP2588114A1 (en) 2013-05-08
JP5810159B2 (ja) 2015-11-11
PE20161410A1 (es) 2017-01-10
HUS2000016I1 (hu) 2020-07-28
BR112012033391A8 (pt) 2018-04-17
CA3061421A1 (en) 2012-01-05
HUE058176T2 (hu) 2022-07-28
US11452695B2 (en) 2022-09-27
US20230046871A1 (en) 2023-02-16
FR20C1020I1 (fr) 2020-08-07
FR22C1031I1 (fr) 2022-09-09
EA201291372A1 (ru) 2013-06-28
KR20170085604A (ko) 2017-07-24
EP3632448B1 (en) 2022-01-12
CA3061421C (en) 2021-06-01
US11478487B1 (en) 2022-10-25
SI2588114T1 (sl) 2020-07-31
US11951213B2 (en) 2024-04-09
EP2588114B1 (en) 2019-12-25
PL3632448T3 (pl) 2022-05-02
NO2020015I1 (no) 2020-06-11
CY1125061T1 (el) 2023-06-09
KR102164693B1 (ko) 2020-10-13
CA2803721C (en) 2018-06-12
EP4056186A1 (en) 2022-09-14
BR112012033391B1 (pt) 2020-02-27
LTPA2022513I1 (pt) 2022-07-11
HRP20220332T1 (hr) 2022-05-13
EP3632448A1 (en) 2020-04-08
CY1122544T1 (el) 2021-01-27
EA028680B1 (ru) 2017-12-29
SI3632448T1 (sl) 2022-04-29
HUS2200018I1 (hu) 2022-06-28
AR081670A1 (es) 2012-10-10
AU2011273605A1 (en) 2013-01-17
CA2803721A1 (en) 2012-01-05
KR20130048227A (ko) 2013-05-09
US11491113B1 (en) 2022-11-08
KR20210013663A (ko) 2021-02-04
RS59826B1 (sr) 2020-02-28
ES2908657T3 (es) 2022-05-03
US11504334B2 (en) 2022-11-22
DK3632448T3 (da) 2022-02-07
US20230372248A1 (en) 2023-11-23
JP2013529665A (ja) 2013-07-22
KR102539030B1 (ko) 2023-05-31
PT3632448T (pt) 2022-03-07
US20220339165A1 (en) 2022-10-27
US20220339107A1 (en) 2022-10-27
PL2588114T3 (pl) 2020-05-18
NZ605176A (en) 2015-02-27
RS63027B1 (sr) 2022-04-29
US20220339106A1 (en) 2022-10-27
AU2011273605B2 (en) 2016-05-26
US20220241209A1 (en) 2022-08-04
FR22C1031I2 (fr) 2023-12-22
CA3003062A1 (en) 2012-01-05
CA3003062C (en) 2019-12-31
AU2011273605A8 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
BR112012033391A2 (pt) kit contraceptivo, método contraceptivo para uma paciente do sexo feminino necessitando do mesmo e composição farmacêutica compreendendo drospirenova.
PH12016500024A1 (en) Bromodomain inhibitor
IL232267A (en) Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective
EP3260463A4 (en) Deuterated chenodeoxycholic acid derivative and pharmaceutical composition comprising compound thereof
PH12014502040A1 (en) Heterocyclyl compounds
ECSP11011276A (es) Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma.
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
PH12015501609A1 (en) Phenicol antibacterials
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
BR112013015796A2 (pt) composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, método de preparar um quelante 18f-nota, e, composição farmacêutica.
MX2013001677A (es) Formulaciones estables de linaclotida.
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR112013014189A8 (pt) composição farmacêutica, uso de um agente de potencialização e uso de uma composição
EA201690005A1 (ru) Состав с модифицированной кинетикой высвобождения
BR112012027393A2 (pt) composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer
EP2983684B8 (en) Essential oil and aloe for treatment and prophylaxis of inflammations caused by demodex, especially marginal blepharitis, a pharmaceutical composition containing essential oil and/or aloe and the use of essential oil and aloe and their compositions for the production of a preparation used in treatment and prophylaxis of the mentioned inflammations
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
EA201400444A1 (ru) Производные 2-оксопиперидинила
CR20120461A (es) Hidrato del hidrobromuro de agomelatina y preparación de éste
MX2019004393A (es) Composicion farmaceutica que comprende drospirenona y kit anticonceptivo.
MX2015011101A (es) Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos.
MX2015008330A (es) Composiciones farmaceuticas veterinarias novedosas y un metodo para la produccion de las mismas.
BR112014009217A2 (pt) antibacterianos à base de fenicol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: LABORATORIOS LEON FARMA, S.A. (ES) , EXELTIS FRANC

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: LABORATORIOS LEON FARMA, S.A. (ES)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/06/2011, OBSERVADAS AS CONDICOES LEGAIS.